MX370375B - Cristal de derivado de azol-benceno. - Google Patents

Cristal de derivado de azol-benceno.

Info

Publication number
MX370375B
MX370375B MX2017000513A MX2017000513A MX370375B MX 370375 B MX370375 B MX 370375B MX 2017000513 A MX2017000513 A MX 2017000513A MX 2017000513 A MX2017000513 A MX 2017000513A MX 370375 B MX370375 B MX 370375B
Authority
MX
Mexico
Prior art keywords
crystal
benzene derivative
azole benzene
azole
dimethylpropoxy
Prior art date
Application number
MX2017000513A
Other languages
English (en)
Other versions
MX2017000513A (es
Inventor
Kawana Asahi
Miyazawa Yuki
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of MX2017000513A publication Critical patent/MX2017000513A/es
Publication of MX370375B publication Critical patent/MX370375B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención proporciona un cristal del ácido 2-[4-(2,2-dimetilpropoxi)-3-(1H-1,2,3,4-tetrazol-1-il)fenil]-4-me til-1,3-tiazol-5-carboxílico, dicho cristal es útil como un agente terapéutico o un agente profiláctico para gota, hiperuricemia, y similares.
MX2017000513A 2014-07-30 2015-07-29 Cristal de derivado de azol-benceno. MX370375B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014155031 2014-07-30
PCT/JP2015/071512 WO2016017696A1 (ja) 2014-07-30 2015-07-29 アゾールベンゼン誘導体の結晶

Publications (2)

Publication Number Publication Date
MX2017000513A MX2017000513A (es) 2017-04-27
MX370375B true MX370375B (es) 2019-12-11

Family

ID=55217594

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017000513A MX370375B (es) 2014-07-30 2015-07-29 Cristal de derivado de azol-benceno.

Country Status (30)

Country Link
US (1) US9815826B2 (es)
EP (1) EP3176165B1 (es)
JP (1) JP6230713B2 (es)
KR (1) KR20170033321A (es)
CN (1) CN106536519B (es)
AR (1) AR101363A1 (es)
AU (1) AU2015297489B2 (es)
BR (1) BR112017001659A2 (es)
CA (1) CA2955485A1 (es)
CY (1) CY1120933T1 (es)
DK (1) DK3176165T3 (es)
ES (1) ES2693382T3 (es)
HR (1) HRP20181789T1 (es)
IL (1) IL250144B (es)
LT (1) LT3176165T (es)
MX (1) MX370375B (es)
MY (1) MY179339A (es)
NZ (1) NZ729045A (es)
PH (1) PH12017500123A1 (es)
PL (1) PL3176165T3 (es)
PT (1) PT3176165T (es)
RS (1) RS57797B1 (es)
RU (1) RU2675854C2 (es)
SA (1) SA517380786B1 (es)
SG (1) SG11201700742UA (es)
SI (1) SI3176165T1 (es)
TR (1) TR201818775T4 (es)
TW (1) TWI687418B (es)
WO (1) WO2016017696A1 (es)
ZA (1) ZA201700491B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201300552D0 (en) * 2013-01-14 2013-02-27 Moog Bv Motion simulator
JP6134072B2 (ja) * 2014-07-30 2017-05-24 帝人ファーマ株式会社 キサンチンオキシダーゼ阻害薬

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122008000051I1 (de) * 1990-11-30 2009-02-05 Teijin Ltd 2-arylthiazolderivat sowie dieses enthaltendes arzneimittel
ATE270550T1 (de) * 1995-04-07 2004-07-15 Teijin Ltd Wirkstoff zum schutz für organ oder gewebe
JP2002105067A (ja) 2000-09-28 2002-04-10 Teijin Ltd ２−フェニルチアゾール誘導体、およびそれを有効成分とする医薬組成物
AU2003290779A1 (en) * 2002-11-14 2004-06-03 Celmed Oncology (Usa), Inc. Peptide deformylase activated prodrugs
WO2007043400A1 (ja) * 2005-10-07 2007-04-19 Kissei Pharmaceutical Co., Ltd. 含窒素芳香族複素環化合物およびそれを含有する医薬組成物
WO2008126770A1 (ja) * 2007-04-05 2008-10-23 Astellas Pharma Inc. トリアリールカルボン酸誘導体の製造方法
CA2682393C (en) * 2007-04-11 2015-03-17 Kissei Pharmaceutical Co., Ltd. 5-membered heterocyclic derivative and use thereof for medical purposes
WO2010018458A2 (en) 2008-08-12 2010-02-18 Crystalgenomics, Inc. Phenol derivatives and methods of use thereof
WO2010128163A2 (en) 2009-05-08 2010-11-11 Pike Pharma Gmbh Small molecule inhibitors of influenza a and b virus and respiratory syncytial virus replication
EP2536699A2 (en) 2010-02-19 2012-12-26 Cadila Healthcare Limited Substantially pure salts of febuxostat and processes for preparation thereof
WO2011139886A2 (en) 2010-04-29 2011-11-10 Dr. Reddy's Laboratories Ltd. Preparation of febuxostat
TWI606048B (zh) * 2013-01-31 2017-11-21 帝人製藥股份有限公司 唑苯衍生物

Also Published As

Publication number Publication date
PH12017500123B1 (en) 2017-05-29
DK3176165T3 (da) 2019-01-02
IL250144A0 (en) 2017-03-30
RU2017106058A (ru) 2018-08-28
ZA201700491B (en) 2018-04-25
RU2017106058A3 (es) 2018-08-28
EP3176165B1 (en) 2018-09-26
US20170210735A1 (en) 2017-07-27
MY179339A (en) 2020-11-04
TW201619153A (zh) 2016-06-01
WO2016017696A1 (ja) 2016-02-04
PL3176165T3 (pl) 2019-03-29
EP3176165A1 (en) 2017-06-07
KR20170033321A (ko) 2017-03-24
AU2015297489B2 (en) 2019-09-19
MX2017000513A (es) 2017-04-27
SA517380786B1 (ar) 2021-01-17
CY1120933T1 (el) 2019-12-11
IL250144B (en) 2019-11-28
CA2955485A1 (en) 2016-02-04
TR201818775T4 (tr) 2019-01-21
AU2015297489A1 (en) 2017-03-09
US9815826B2 (en) 2017-11-14
RS57797B1 (sr) 2018-12-31
NZ729045A (en) 2022-05-27
ES2693382T3 (es) 2018-12-11
TWI687418B (zh) 2020-03-11
SI3176165T1 (sl) 2018-11-30
SG11201700742UA (en) 2017-03-30
JP6230713B2 (ja) 2017-11-15
AR101363A1 (es) 2016-12-14
HRP20181789T1 (hr) 2018-12-28
PT3176165T (pt) 2019-01-10
CN106536519B (zh) 2019-03-29
EP3176165A4 (en) 2017-06-07
LT3176165T (lt) 2018-11-26
BR112017001659A2 (pt) 2018-01-30
JPWO2016017696A1 (ja) 2017-04-27
PH12017500123A1 (en) 2017-05-29
RU2675854C2 (ru) 2018-12-25
CN106536519A (zh) 2017-03-22

Similar Documents

Publication Publication Date Title
CY1120454T1 (el) Παραγωγα 2,4-θειαζολιδινεδιονης στη θεραπεια διαταραχων του κεντρικου νευρικου συστηματος
EP3119753A4 (en) 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and processes for their preparation
SI3097098T1 (sl) Postopek za pripravo N-((3-aminooksetana-3-il)metil)-2-(1,1-diokso- 3,5-dihidro-1,4-benzotiazepin-4-il)-6-metil-kinazolin-4-amina
EP3119756A4 (en) 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and processes for their preparation
HK1258053A1 (zh) 作為蛋白激酶抑制劑的新的2，3，5-取代的噻吩化合物
EP3652133A4 (en) MIXTURES INCLUDING A UREASE INHIBITOR (IU) AND A NITRIFICATION INHIBITOR SUCH AS 2- (3,4-DIMETHYL-1H-PYRAZOL-1-YL) SUCCINIC ACID (DMPSA) OR 3,4-DIMETHYL PYRAZOLIUM GLYCOLATE (DMPG)
UY37517A (es) Métodos de síntesis de compuestos tiazoles sustituidos
EP3279202A4 (en) Crystal of 3,5-disubstituted benzene alkynyl compound
EP3666770A4 (en) NEW HETEROCYCLIC COMPOUNDS AS CDK8 / 19 INHIBITORS
MX2023001805A (es) Formas solidas de 2-(5-(4-(2-morfolinoetoxi)fenil)piridin-2-il)-n- bencilacetamida.
SG10201913049QA (en) Composition comprising an anti-abeta protofibril antibody and a beta-secretase bace1 inhibitor for the treatment of alzheimer's disease
HUE045851T2 (hu) Eljárás 2-(2,5-dimetil-1H-pirrol-1-il)-1,3-propándiol és helyettesített származékainak elõállítására
PH12017500123A1 (en) Crystal of azole benzene derivative
EP3661505A4 (en) BENZOTHIAZOLE AND RELATED COMPOUNDS
NZ716494A (en) Processes and intermediates for the preparation of a pde10 inhibitor
PH12017500124A1 (en) Azole benzene derivative and crystalline form thereof
SI3164385T1 (sl) Nova polimorfna oblika N-(2-(6-fluoro-LH-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoksi) benzilamin hidroklorida za zdravljenje Alzheimerjeve bolezni
EP3804719A4 (en) USE OF 2,3,5-SUBSTITUTED THIOPHENE COMPOUND TO IMPROVE RADIATION THERAPY
UA98156U (uk) 2-((5-(адамантан-1-іл)-4-феніл-4н-1,2,4-триазол-3-іл)тіо)-n'-(2-нітробензиліден)ацетогідразид, який проявляє антигіпоксичну активність
AR101362A1 (es) Derivado de azol benceno y forma cristalina del mismo
UA97633U (xx) 3-((2-хлоретил)тіо)-5-(4-метоксифеніл)-1н-1,2,4-триазол, що проявляє гіпоглікемічну активність
UA114081U (uk) 5-(2-(4-(диметиламіно)бензиліден)гідразиніл)-4-феніл-4h-1,2,4-триазол-3-тіолу гідрохлорид, що стимулює ріст пшениці озимої
UA94667U (uk) Заміщені [2-(3-r-1h-[1,2,4]триазол-5-іл)феніл]аміни, що проявляють гіпоглікемічну активність
UA99119U (ru) N'-(2-(5-((теофиллин-7-ил)метил)-4-этил-4h-1,2,4-триазол-3-илтио)ацетил)изоникотиногидразид, который проявляет противотуберкулезную активность.
UA98919U (ru) 4-этил-3-(феноксиметил)-5-((2-((5-феноксиметил)-4-фенил-4н-1,2,4-триазол-3-ил)тио)этил)тио)-4н-1,2,4-триазол, проявляющая диуретическую активность

Legal Events

Date Code Title Description
FG Grant or registration